Administer as an IV infusion over 60 min after dilution.
uHCC Patient weighing ≥30 kg 300 mg as a single dose in combination w/ durvalumab 1,500 mg at day 1 of cycle 1, followed by durvalumab as a single agent every 4 wk,
<30 kg 4 mg/kg as a single dose in combination w/ durvalumab 20 mg/kg at day 1 of cycle 1, followed by durvalumab as a single agent every 4 wk.
Metastatic NSCLC Patient weighing ≥30 kg 75 mg every 3 wk in combination w/ durvalumab 1,500 mg & platinum-based chemotherapy for 4 cycles, & then administer durvalumab 1,500 mg every 4 wk as a single agent w/ histology-based pemetrexed therapy every 4 wk, & a 5th dose of Imjudo 75 mg in combination w/ durvalumab dose 6 at wk 16,
<30 kg 1 mg/kg every 3 wk in combination w/ durvalumab 20 mg/kg & platinum-based chemotherapy for 4 cycles, & then administer durvalumab 20 mg/kg every 4 wk as a single agent w/ histology-based pemetrexed therapy every 4 wk, & a 5th dose of Imjudo 1 mg/kg in combination w/ durvalumab dose 6 at wk 16.
Sign Out
